In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 57-62

  Tawara, Shuichi ^a   Ikeda, Fumiaki ^a   Maki, Katsuyuki ^a   Morishita, Yoshihiko ^a   Otomo, Kazumi ^a   Teratani, Noriko ^a   Goto, Toshio ^a   Tomishima, Masaki ^a   Ohki, Hidenori ^a   Yamada, Akira ^a   Kawabata, Koji ^a   Takasugi, Hisashi ^a   Sakane, Kazuo ^a   Tanaka, Hirokazu ^a   Matsumoto, Fumio ^b   Kuwahara, Shogo ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b Kanagawa Pref Nursing Hygienic S   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; HUMAN SERUM ALBUMIN; ITRACONAZOLE; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033989710     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.57-62.2000     Document Type: Article

References (19)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41: 2333-2338.
2. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. M. Balkovec. 1997. Antimicrob. Agents Chemother. 41:2326-2332.
3. Bartizal, K., T. Scott, G. K. Abruzzo, C. J. Gill, C. Pacholok, L. Lynch, and H. Kropp. 1995. In vitro evaluation of the pneumocandin antifungal agent L-733,560, a new water-soluble hybrid of L-705,589 and L-731,373. Antimicrob. Agents Chemother. 39:1070-1076.
4. Beaulieu, D., J. Tang, D. J. Zeckner, and T. R. Parr, Jr. 1993. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-β-D-glucan synthase. FEMS Microbiol. Lett. 108:133-138.
5. Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497.
6. Hitchcock, C. A., G. W. Pye, D. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
7. Huang, A., F. Edwards, E. M. Bernard, D. Armstrong, and H. J. Schmitt. 1990. In vitro activity of the new semisynthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 9:697-699.
8. Ingroff, A. E. 1998. Comparison of the in vitro activities of the new triazole SCH55592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
9. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
10. Kurtz, M. B., C. Douglas, J. Marrinan, K. Nollstadt, J. Onishi, S. Dreikorn, J. Millican, S. Mandara, J. Thompson, J. M. Balkovec, F. A. Bouffard, J. F. Dropinski, M. L. Hammond, R. A. Zambias, G. Abruzzo, K. Bartizal, O. B. Mcmanus, and M. L. Garcia. 1994. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. 38:2750-2757.
11. Kurtz, M. B., E. M. Bernard, F. F. Edwards, J. A. Marrinan, J. Dropinski, C. M. Douglas, and D. Armstrong. 1995. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 39:1784-1789.
12. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42:2726-2730.
14. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
15. Poeta, M. D., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41:1835-1836.
16. Thomas, A. H. 1986. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J. Antimicrob. Chemother. 17:269-279.
17. Vazquez, J. A., M. Lynch, and J. D. Sobel. 1995. In vitro activity of a new pneumocandin antifungal agent, L-733,560, against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob. Agents Chemother. 39:2689-2691.
18. Verweiji, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
19. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kobani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.